This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the treatment landscape and the potential of Patisiran in patients with ATTR-CM in light of the recent data presented from the 18 months result of the APOLLO-B Phase 3 Study.

Ticker(s): ALNY

Who's the expert?

Institution: Sharp HealthCare San Diego

  • Interventional cardiologist fellowship trained at Northwestern.
  • Treats 300 patients with chronic heart failuer and has prescribed Verquvo for 5 patients.
  • Has numerous publications and grants, with a specific focus on novel therapeutic procedures in patients with structural heart disease and high-risk coronary interventions.

Interview Goal
This interview will focus on discussing the use of Patisiran in patients with ATTR-CM

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.